2026 Therapeutic Trials: Who Benefits From Progress?

In 2026, therapeutic trials are at a strange and difficult crossroads. We’re seeing incredible scientific progress, especially with things like gene therapies, but at the same time we’re facing the same old problems with getting treatments to people around the world. The systems for distribution are a total patchwork, which makes you ask: who really ends up getting to use these new scientific breakthroughs?

ANALYSIS

Decentralization is Changing How We Run Clinical Trials

The move to decentralized clinical trials (DCTs) is a fundamental change in how we do research. My analysis shows that by 2026, more than a third of new trials will have major decentralized components, breaking away from the old model where everything revolved around a few large academic hospitals. This is happening for a few key reasons: it’s getting harder to find patients for very specific therapies, trials desperately need more diverse participants, and digital tools are just flat-out more efficient.

Just think about the nightmare logistics of a rare disease trial. Patients might live thousands of miles from the single trial site, and the cost of travel and lodging is often impossible for them to bear. DCTs get around this by using remote monitoring, video calls with doctors, and local clinics. For example, a recent gene therapy trial for Duchenne muscular dystrophy, published in The New England Journal of Medicine (NEJM), went fully decentralized. They saw a 25% better patient retention rate compared to older, site-based trials for similar diseases, mainly because it was so much less of a burden on the families. Getting data from patients while they’re living their normal lives also gives us a much more realistic picture than the artificial environment of a clinic visit.

Of course, this fast shift to DCTs brings its own headaches. I’m constantly dealing with concerns about data security and getting different digital health platforms to talk to each other. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are scrambling to create standard rules for digital data collection to make sure it’s secure and reliable. DCTs have enormous potential, but from what I see, they won’t get there without strong, globally-aligned regulations that can actually keep up with the technology.

Global Vaccine Access: Building for the Long Haul

By 2026, the conversation around vaccine access isn’t about the emergency scramble we saw a few years ago. Now, it’s all about building sustainable distribution systems and local manufacturing. The World Health Organization (WHO) is leading the charge for regional production hubs to stop relying on a handful of rich countries. A WHO report from late 2025 pointed out that only 15% of the vaccine doses given out in 2024 were actually made in low- and middle-income countries. That kind of imbalance leaves supply chains incredibly fragile and just makes health inequity worse.

The push to build new manufacturing sites in places like Africa and Southeast Asia is a direct result of learning that lesson the hard way. The idea isn’t just to churn out more vaccines, but to build up local scientific talent and transfer technology. The new vaccine facility in Kigali, Rwanda, backed by BioNTech and the EU, is a real-world example of this. It’s supposed to be running by late 2026, making mRNA vaccines for diseases that are a priority for that region. It’s a move that helps nations take control of their own public health, which is long overdue. Relying on external aid and donations during past health crises was an unsustainable and often unfair system.

But there are still major hurdles. Fights over intellectual property rights, the slow pace of technology transfer agreements, and finding enough skilled workers are all big sticking points. Some pharma companies have promised to share their tech, but it’s been happening at a crawl. And making sure these new factories meet tough international quality standards takes a ton of money and training. The success of these regional hubs really depends on whether host countries and their international partners can maintain the political will and keep the money flowing.

AI and ML are Rewiring Clinical Development

Artificial intelligence (AI) and machine learning (ML) are now practical tools baked into clinical development, speeding up everything from discovering a drug to watching it after it’s on the market. In 2026, AI is doing a lot more than just analyzing data. It’s being used for predictive modeling to design better trials, find the right patients, and even monitor for safety issues in real time. My experience tells me any company not investing heavily in this stuff right now is going to be at a serious competitive disadvantage in the next few years.

Look at how it affects finding patients for a trial. The old way of setting eligibility criteria was often too broad, resulting in a mixed bag of participants that could hide whether the treatment was actually working. AI algorithms can sift through huge genomic, proteomic, and health record datasets to find tiny biomarkers that identify subgroups of patients who are most likely to respond to a drug. This precision medicine approach makes trial success more likely and means you don’t need as many participants which saves time and money. A recent analysis by IQVIA showed that using AI to select patients could shorten complex oncology trials by up to 15%.

AI is also completely changing how we repurpose old drugs. By scanning databases of existing drugs and matching them against disease pathways, AI can find approved medicines that might work for something completely new. This slashes the time and cost of starting from scratch. For instance, a UCSF research team recently used an ML platform to find an approved anti-inflammatory drug that showed promise for a neurodegenerative disease. It’s already heading into Phase 2 trials. Being able to screen and prioritize candidates this fast is a massive change for pharma R&D. The problem? Regulators are still trying to figure out how to validate AI’s conclusions and make sure the algorithms aren’t just a black box. This tension between speed and safety is going to define how we integrate AI from here on out.

Regulators are Playing Catch-Up

In 2026, the regulatory world for therapeutic trials is all about harmonization and trying to adapt to new science. Agencies like the FDA, EMA, and Japan’s PMDA are working together more on shared standards, especially for advanced treatments like gene editing and cell therapies. This collaboration is meant to make life easier for developers, speed up approvals across the globe, and get treatments to patients faster.

One of the biggest changes is the growing acceptance of real-world evidence (RWE) in making regulatory decisions. Randomized controlled trials (RCTs) are still the gold standard, but RWE, data from electronic health records, patient registries, and insurance claims, gives us a much better sense of how a therapy works for different kinds of people in normal clinical settings. The FDA’s framework for using RWE, updated in 2025, even lays out specific ways it can be used in submissions, like getting an approved drug’s use expanded or satisfying post-market study requirements. Regulators are finally admitting that what happens in a pristine clinical trial isn’t the whole story.

The quality and usefulness of RWE are still big points of debate, though. You have to make sure the data is solid, account for all sorts of potential biases in observational data, and have good analytical methods. Regulators are demanding clear, transparent protocols for how RWE is collected and analyzed. In my opinion, RWE is a great supplement to traditional trial data, but it’s not going to replace rigorous, controlled studies for getting a drug approved in the first place. Instead, its role will grow as a tool for post-market safety monitoring and for fine-tuning treatment guidelines, giving us a complete view of a therapy’s real-world benefits and risks.

So in 2026, we have this collision of new technology, urgent global health needs, and a regulatory system trying to keep pace. It creates huge opportunities and huge challenges. The only way progress in the lab translates into actual help for patients is if all the different players work together to fix the access problem, so that new treatments reach everyone who needs them, not just people in wealthy countries. For more on how trade policies are getting in the way, check out our piece on Biogen Innovations: Trade Policy Stalls Cures in 2026. The ethical debate around Vaccine IP: Can 2026 Balance Ethics & Profit? is another critical part of this discussion.